Skip to main content

Table 1 Basic Characteristics of four passages patients

From: Epidemiological and clinical based study on four passages of COVID-19 patients: intervention at asymptomatic period contributes to early recovery

  Numbers (%)  
Passage 1 (n = 1) Passage 2 (n = 8) Passage 3 (n = 23) Passage 4 (n = 46) p values
Age Median 48.00 51.50 48.00 44.00 0.19
Gender
 Female 0 4 (50.00) 10 (43.48) 20 (43.47) 0.40
 Male 1 4 (50.00) 13 (56.52) 26 (56.53)
Symptoms
 Fever 1 7 (87.50) 16 (69.57) 26 (56.52) 0.19
 Cough 1 8 (100.00) 18 (78.26) 38 (82.61) 0.36
 Fatigue 1 8 (100.00) 23 (100.00) 44 (95.65) 0.50
 Headache 0 1 (12.50) 2 (8.70) 1 (2.17) 0.32
 Anorexia 0 1 (12.50) 4 (17.39) 12 (26.08) 0.56
 Diarrhear 0 0 (0.00) 0 (0.00) 0 (0.00)  
 Nasal congestion 0 0 (0.00) 1 (4.35) 0 (0.00) 0.30
 Pharyngalgia 1 4 (50.00) 10 (43.48) 7 (15.22) 0.01
 Lymphadenopathy 0 0 (0.00) 0 (0.00) 0 (0.00)  
 Myalgia 1 1 (12.50) 1 (4.35) 7 (15.22) 0.41
 Dyspnea 0 2 (25.00) 1 (4.35) 0 (0.00) 0.003
 Vomit 0 0 (0.00) 1 (4.35) 1 (2.17) 0.77
 Abdomin pain 0 1 (12.50) 1 (4.35) 0 (0.00) 0.10
Comorbidities
 Hypertension 0 4 (50.00) 6 (26.09) 9 (19.57) 0.18
 Diabetes 0 4 (25.00) 3 (0.00) 1 (0.00) < 0.001
 Tuberculosis 0 3 (37.50) 1 (4.35) 3 (6.52) 0.01
 Hepatitis B 0 0 (0.00) 1 (4.35) 2 (4.35) 0.83
 Cardiovascular disease 0 0 (0.00) 1 (4.35) 0 (0.00) 0.30
 COPD 0 1 (12.50) 0 (0.00) 0 (0.00) 0.01
 Malignancy 0 0 (0.00) 0 (0.00) 0 (0.00)  
 Chronic kidney Disease 0 0 (0.00) 0 (0.00) 0 (0.00)  
 Chronic liver disease 0 0 (0.00) 0 (0.00) 0 (0.00)  
 HIV 0 0 (0.00) 0 (0.00) 0 (0.00)  
Medium incubation days 9.00 7.00 (2–12) 8.00 (4–13) 10.00 (7–15) 0.005
  1. P values indicate differences among Passage 2, Passage 3 and Passage 4 patients. P < 0.05 was considered statistically significant. The comparisons of the clinical characteristics, excluding age and incubation days, were performed by χ2 test. a The comparison of age and the comparison of incubation days among different groups was performed by one-way ANOVA with Bonferroni’s post-test